Scientific Reports (Jan 2021)

Effect of SSRI exposure on the proliferation rate and glucose uptake in breast and ovary cancer cell lines

  • Britta Stapel,
  • Catharina Melzer,
  • Juliane von der Ohe,
  • Peter Hillemanns,
  • Stefan Bleich,
  • Kai G. Kahl,
  • Ralf Hass

DOI
https://doi.org/10.1038/s41598-020-80850-9
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Breast cancer is the most prevalent malignancy amongst women worldwide while ovarian cancer represents the leading cause of death among gynecological malignancies. Women suffering from these cancers displayed heightened rates of major depressive disorder, and antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs) is frequently recommended. Recently, narrative reviews and meta-analyses showed increased recurrence risks and mortality rates in SSRI-treated women with breast and ovarian cancer. We therefore examined whether three commonly prescribed SSRIs, fluoxetine, sertraline and citalopram, affect proliferation or glucose uptake of human breast and ovarian cancer cell lines characterized by different malignancies and metastatic potential. SSRI treatment or serotonin stimulation with therapeutically relevant concentrations over various time periods revealed no consistent dose- or time-dependent effect on proliferation rates. A marginal, but significant increase in glucose uptake was observed in SK-OV-3 ovarian cancer cells upon fluoxetine or sertraline, but not citalopram treatment. In three breast cancer cell lines and in two additional ovarian cancer cell lines no significant effect of SSRIs on glucose uptake was observed. Our data suggest that the observed increase in recurrence- and mortality rates in SSRI-treated cancer patients is unlikely to be linked to antidepressant therapies.